Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle
If there’s one lesson that shines through in the retrenchment going on now in biotech, it’s that no great startup story — regardless of its distinguished scientific founders, the deep-pocket investors who launched the company, or the blue-chip look of its IPO — can survive without solidly positive human data.
And the blight of disappointing data has now afflicted another former high flyer in the immunotherapy field.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.